Tag: Press Release

Cambridge, MA, USA – November 18, 2025: Vincere Biosciences today announced the receipt of a $5 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through its Therapeutics Pipeline Program, which supports the advancement of promising therapies through preclinical and clinical stages. The initiative focuses on candidates with strong potential to slow...

Nov 7, 2025 – Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery and development company, today announced the launch of its innovative cardiometabolic disease portfolio of unique highly-differentiated molecules discovered using generative AI. Powered by Insilico’s proprietary end-to-end Pharma.AI platform, the portfolio covers a range of diverse mechanisms and stages from early...

Spanning 350 square metres, the new Centre brings together state-of-the art facilities within an integrated multidisciplinary framework to enable clinical research and implementation of gerodiagnostics and gerotherapeutics, enhancing and optimising healthspan throughout the adult lifespan and setting new benchmarks for healthy longevity research and innovation. Singapore, 10 October 2025 — The Yong Loo Lin School...

The Alliance for Longevity Science, Arts & Entertainment (ALSAE)—pronounced “all say”—today announced its official launch, pioneering a new nonprofit effort to accelerate progress against the chronic diseases of aging by bridging breakthroughs in longevity science with the transformative influence of arts and entertainment. Longevity science (sometimes called geroscience) marks a revolutionary shift—moving beyond traditional biomedical research...

HackAging.ai is the global online hackathon at the intersection of Agentic AI and longevity science, bringing together researchers, founders, and engineers to accelerate solutions that extend healthy human lifespan. Turn two weeks into a job, a useful tool, a collaboration, or a company. The event is sponsored by Retro.bio, Gero, Bio Protocol, VitaDAO, AthenaDAO, Immortal...

YouthBio Therapeutics, a biotechnology company pioneering partial cellular reprogramming to treat diseases of aging, today announced a successful INTERACT meeting with the FDA for its lead Alzheimer's candidate, YB002. In its formal response, the FDA agreed that existing preclinical data support the bioactivity of YB002 and YouthBio's proposed first-in-human trial. This feedback represents a major...